• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Diabetic Foot Infection (DFI) - Pipeline Review, Q3 2011 - Product Image

Diabetic Foot Infection (DFI) - Pipeline Review, Q3 2011

  • ID: 1845432
  • July 2011
  • 32 pages
  • Global Markets Direct

Diabetic Foot Infection (DFI) - Pipeline Review, Q3 2011

Summary

Global Markets Direct’s, 'Diabetic Foot Infection (DFI) - Pipeline Review, Q3 2011', provides an overview of the Diabetic Foot Infection (DFI) therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Foot Infection (DFI), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Foot Infection (DFI). 'Diabetic Foot Infection (DFI) - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Diabetic Foot Infection (DFI).
- A review of the Diabetic READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Diabetic Foot Infection (DFI) Overview
Therapeutics Development
An Overview of Pipeline Products for Diabetic Foot Infection (DFI)
Diabetic Foot Infection (DFI) Therapeutics under Development by Companies
Diabetic Foot Infection (DFI) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Diabetic Foot Infection (DFI) Therapeutics - Products under Development by Companies
Diabetic Foot Infection (DFI) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Diabetic Foot Infection (DFI) Therapeutics Development
Warner Chilcott Limited
Theravasc, Inc.
Diabetic Foot Infection (DFI) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
TV1001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nemonoxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Daptomycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Umbilical Cord Mesenchymal Stem Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Doxium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Diabetic Foot Infection (DFI) - Featured News
Mar 15, 2010: TaiGen's Nemonoxacin Once-A-Day Oral Dosing Meets Primary Endpoints In Diabetic Foot Infection Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Diabetic Foot Infection (DFI), Q3 2011
Products under Development for Diabetic Foot Infection (DFI) – Comparative Analysis, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Comparative Analysis by Late Stage Development, Q3 2011
Comparative Analysis by Mid Clinical Stage Development, Q3 2011
Comparative Analysis by Early Clinical Stage Development, Q3 2011
Comparative Analysis by Pre-Clinical Stage Development, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Warner Chilcott Limited, 2011
Theravasc, Inc., 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011

List of Figures
Number of Products under Development for Diabetic Foot Infection (DFI), Q3 2011
Products under Development for Diabetic Foot Infection (DFI) – Comparative Analysis, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Late Stage Products, Q3 2011
Mid Clinical Stage Products, Q3 2011
Early Clinical Stage Products, Q3 2011
Pre-Clinical Stage Products, Q3 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Route of Administration, Q3 2011
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Assessment by Stage and Molecule Type, Q3 2011

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos